Close Menu

heart transplant

The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.

The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.

The diagnostic will now be a contracted service with Anthem Blue Cross of California and 10 of its affiliated health plans.

The acquisition of OTTR Complete Transplant Management will enable CareDx to integrate the EMRs of patients at transplant centers with longitudinal patient surveillance data.

The company said its testing services revenues for the quarter rose nearly 120 percent year over year.

The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.

The investment bank said the company is strongly positioned as a leader in the transplant diagnostics market with tests that serve an unmet need.

The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.

The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.

The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.

Pages

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.